125 related articles for article (PubMed ID: 24766516)
1. Desmoteplase as a potential treatment for cerebral ischaemia.
Patel R; Ispoglou S; Apostolakis S
Expert Opin Investig Drugs; 2014 Jun; 23(6):865-73. PubMed ID: 24766516
[TBL] [Abstract][Full Text] [Related]
2. Technology evaluation: desmoteplase, PAION/Forest.
Debens T
Curr Opin Mol Ther; 2004 Oct; 6(5):567-75. PubMed ID: 15537059
[TBL] [Abstract][Full Text] [Related]
3. The use of desmoteplase (bat saliva) in the treatment of ischaemia.
Piechowski-Jozwiak B; Bogousslavsky J
Expert Opin Biol Ther; 2013 Mar; 13(3):447-53. PubMed ID: 23394378
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
[TBL] [Abstract][Full Text] [Related]
5. Desmoteplase in the treatment of acute ischemic stroke.
Dafer RM; Biller J
Expert Rev Neurother; 2007 Apr; 7(4):333-7. PubMed ID: 17425487
[TBL] [Abstract][Full Text] [Related]
6. Desmoteplase.
Paciaroni M; Medeiros E; Bogousslavsky J
Expert Opin Biol Ther; 2009 Jun; 9(6):773-8. PubMed ID: 19456211
[TBL] [Abstract][Full Text] [Related]
7. [Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].
Paris C; Derex L
Rev Neurol (Paris); 2015 Dec; 171(12):866-75. PubMed ID: 26563662
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects.
López-Atalaya JP; Roussel BD; Ali C; Maubert E; Petersen KU; Berezowski V; Cecchelli R; Orset C; Vivien D
Stroke; 2007 Mar; 38(3):1036-43. PubMed ID: 17325305
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.
Röther J; Ford GA; Thijs VN
Cerebrovasc Dis; 2013; 35(4):313-9. PubMed ID: 23615379
[TBL] [Abstract][Full Text] [Related]
10. Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials.
Elmaraezy A; Abushouk AI; Saad S; Eltoomy M; Mahmoud O; Hassan HM; Aboelmakarem A; Fotoh AA; Althaher F; Huy NT; Hirayama K
CNS Neurol Disord Drug Targets; 2017; 16(7):789-799. PubMed ID: 27978795
[TBL] [Abstract][Full Text] [Related]
11. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection.
Schleuning WD
Haemostasis; 2001; 31(3-6):118-22. PubMed ID: 11910176
[TBL] [Abstract][Full Text] [Related]
12. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program.
von Kummer R; Albers GW; Mori E;
Int J Stroke; 2012 Oct; 7(7):589-96. PubMed ID: 22989394
[TBL] [Abstract][Full Text] [Related]
13. t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions.
Freeman R; Niego B; Croucher DR; Pedersen LO; Medcalf RL
Brain Res; 2014 May; 1565():63-73. PubMed ID: 24675027
[TBL] [Abstract][Full Text] [Related]
14. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).
von Kummer R; Mori E; Truelsen T; Jensen JS; Grønning BA; Fiebach JB; Lovblad KO; Pedraza S; Romero JM; Chabriat H; Chang KC; Dávalos A; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A; Albers GW;
Stroke; 2016 Dec; 47(12):2880-2887. PubMed ID: 27803391
[TBL] [Abstract][Full Text] [Related]
15. Vampire bats yield potent clot buster for ischemic stroke.
Grandjean C; McMullen PC; Newschwander G
J Cardiovasc Nurs; 2004; 19(6):417-20. PubMed ID: 15529064
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis of thrombolysis and its clinical application in stroke.
Murray V; Norrving B; Sandercock PA; Terént A; Wardlaw JM; Wester P
J Intern Med; 2010 Feb; 267(2):191-208. PubMed ID: 20175866
[TBL] [Abstract][Full Text] [Related]
17. Desmoteplase in acute massive pulmonary thromboembolism.
Tebbe U; Bramlage P; Graf A; Lechleitner P; Bode C; Riess FC; Clemens N; Al-Rawi Y; Konstantinides S; Goldhaber SZ
Thromb Haemost; 2009 Mar; 101(3):557-62. PubMed ID: 19277420
[TBL] [Abstract][Full Text] [Related]
18. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.
Hacke W; Furlan AJ; Al-Rawi Y; Davalos A; Fiebach JB; Gruber F; Kaste M; Lipka LJ; Pedraza S; Ringleb PA; Rowley HA; Schneider D; Schwamm LH; Leal JS; Söhngen M; Teal PA; Wilhelm-Ogunbiyi K; Wintermark M; Warach S
Lancet Neurol; 2009 Feb; 8(2):141-50. PubMed ID: 19097942
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.
Piechowski-Jozwiak B; Abidi E; El Nekidy WS; Bogousslavsky J
Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):165-176. PubMed ID: 34893967
[TBL] [Abstract][Full Text] [Related]
20. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase.
Fiebach JB; Al-Rawi Y; Wintermark M; Furlan AJ; Rowley HA; Lindstén A; Smyej J; Eng P; Warach S; Pedraza S
Stroke; 2012 Jun; 43(6):1561-6. PubMed ID: 22474060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
